inHEART

inHEART develops an AI-enabled digital twin platform for cardiac care, specializing in image-guided ablation procedures for ventricular tachycardia (VT) and other arrhythmias. The company's core offering is a proprietary segmentation algorithm that analyzes CT and MR images to create detailed 3D anatomical cardiac models, enabling precise identification of arrhythmogenic tissue and substrate characterization. The platform integrates seamlessly with all major electroanatomic mapping (EAM) systems for real-time procedural guidance. Clinical evidence demonstrates 60% reduction in procedure time and 38% reduction in recurrence rates for VT ablations. inHEART serves 300+ partner hospitals across 40+ countries, with 7,500+ supported cases. The company maintains regulatory compliance including SOC 2 and HIPAA certifications. Based in France (Bordeaux/Pessac) with a US office in Cambridge, MA, inHEART operates at the intersection of advanced imaging analytics, AI, and interventional cardiology. The platform has been featured in major cardiac electrophysiology symposia and publications, with endorsements from leading academic electrophysiologists. Recent funding (2024) and board leadership appointments signal continued investment in platform expansion and global market penetration. Target users include cardiac electrophysiologists, interventional cardiologists, and hospital EP labs managing complex arrhythmias.